Trends of drug resistance in M. tuberculosis in a reference laboratory in Central India: Forging ahead towards TB elimination

Author:

Desikan Prabha,Panwalkar NikitaORCID,Rangnekar Aseem,Khan Zeba,Punde Ram Prakash,Sharma Arun Kumar,Kushwaha Ragini,Ponnuraja Chinnaiyan,Anand Sridhar

Publisher

Elsevier BV

Reference6 articles.

1. Global tuberculosis report,2019

2. Trends in burden of multidrug-resistant tuberculosis in countries, regions, and worldwide from 1990 to 2017: results from the Global Burden of Disease study;Ou;Infect Dis Poverty,2021

3. Prevalence and factors associated with multidrug-resistant tuberculosis in South India;Shivekar;Sci Rep,2020

4. Ministry of Health and Family Welfare, HFW/Measures taken to reduce TB cases in India/16 december 2022/3, (release ID: 1884180) visitor counter:1748 posted on: 16 DEC 2022 5:22 PM by PIB Delhi https://www.pib.gov.in/PressReleasePage.aspx?PRID=1884180#:∼:text=Universal%20Drug%20Susceptibility%20Testing%20(UDST,time%20of%20treatment%20initiation%20itself. [accessed 9 August 2023].

5. rpoB mutations causing discordant rifampicin susceptibility in Mycobacterium tuberculosis: retrospective analysis of prevalence, phenotypic, genotypic, and treatment outcomes;Mvelase;Open Forum Infect Dis,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3